health
March 9, 2026
Hims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugs
Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell Novo's branded medicines.
TL;DR
- Novo Nordisk dropped its court proceedings against Hims & Hers.
- Hims & Hers agreed to offer Novo's Ozempic and Wegovy at the same price as other telehealth platforms.
- Hims & Hers will no longer advertise compounded GLP-1 drugs.
- Novo Nordisk CEO Mike Doustdar stated the company reserves the right to restart proceedings if necessary, but does not anticipate doing so.
- Shares of Hims & Hers increased significantly following the announcement.
- The agreement comes after Novo Nordisk had previously sued Hims for selling a cheaper, compounded version of Wegovy.
- The FDA had also taken steps to restrict such practices by compounding pharmacies.
- Hims' existing patients on compounded semaglutide will have the option to transition to FDA-approved medicines.
- Hims CEO Andrew Dudum noted the rapidly evolving landscape of anti-obesity drugs and the demand for affordability and personalization.
Continue reading the original article